Researcher
Karin Vanderkerken
- Research Expertise:
- Basic and translational research in multiple myeloma
- Research for therapies, targeting the myeloma cell in its microenvironment
- Study of functional interaction between the cancer cell and its microenvironment using microarray, realtime PCR and FACS analysis and westernblotting.
- Investigate the influence of histon deacetylase inhibitors (HDAC-I) in 5TMM models.
- Keywords:Medicine, Pharmacy and pharmacology, General and logistic services
- Disciplines:Applied immunology, Cancer biology, Hematology, Cancer therapy
- Users of research expertise:
- Basic and translational research in multiple myeloma
- Research for therapies, targeting the myeloma cell in its microenvironment
- Study of functional interaction between the cancer cell and its microenvironment using microarray, realtime PCR and FACS analysis and westernblotting.
- Investigate the influence of histon deacetylase inhibitors (HDAC-I) in 5TMM models.
Affiliations
- Translational Oncology Research Center (Research group)
Member
From1 Jan 2023 → Today - International Relations and Mobility (Administrative office)
Member
From12 Jun 2024 → Today - Translational Oncology Research Center (Research group)
Member
From3 Jun 2024 → Today - Basic (bio-) Medical Sciences (Department)
Member
From1 Jan 2024 → Today - Translational Oncology Research Center (Research group)
Member
From1 Jan 2024 → Today - R&D centraal (Administrative office)
Member
From1 Jan 2024 → Today - Translational Oncology Research Center (Research group)
Member
From1 Jan 2024 → Today - International Relations and Mobility (Administrative office)
Member
From1 Oct 2022 → Today - R&D centraal (Administrative office)
Member
From1 Oct 2019 → Today - R&D centraal (Administrative office)
Member
From1 Oct 2019 → 30 Sep 2022 - Basic (bio-) Medical Sciences (Department)
Member
From8 Apr 2019 → Today - Basic (bio-) Medical Sciences (Department)
Member
From1 Jan 2014 → 20 Oct 2022 - Immunology and Microbiology (Department)
Member
From1 Jul 2004 → 31 Dec 2013 - Immunology and Microbiology (Department)
Member
From1 May 2003 → 30 Jun 2004 - Immunology and Microbiology (Department)
Member
From1 Jan 1999 → 30 Sep 2007 - FORMER_Hematology (Research group)
Responsible
From1 Oct 1990 → 1 Jan 2023 - Faculty of Medicine and Pharmacy (Faculty)
Member
From1 Oct 1987 → 30 Sep 1994
Projects
1 - 10 of 27
- Erasmus Standard Budget-based + LS Type II : European Universities Transforming to an Open Inclusive Academy - Making Organisational and Real Evolution (EUTOPIA – MORE)From1 Dec 2022 → TodayFunding: EU - out of framework - indefinite
- SRP-Onderzoekszwaartepunt: PACT: multi-omics Profiling of T cells to improve Adoptive Cell TherapyFrom1 Nov 2022 → TodayFunding: BOF - projects
- Nanobody-based AXL targeting and combination treatment for acute myeloid leukemia and multiple myelomaFrom1 Jan 2022 → TodayFunding: FWO research project (including WEAVE projects)
- EUTOPIA - Transformation of Research And INnnovation (TRAIN).From1 Jan 2021 → 31 Dec 2023Funding: H2020-EU.5. - Science with and for society
- Targeting residual, dormant cancer cells in myeloma: a new approachFrom1 Jan 2018 → 31 Dec 2018Funding: FWO research grant KAN
- Strategic Research Programme: Cancer Cell Targeting in Myeloma and Melanoma (MyMe)From1 Nov 2017 → 31 Oct 2024Funding: University - Project driven research
- Study of the immune-modulating effects of epigenetically targeted treatments in multiple myelomaFrom1 Jan 2017 → 31 Dec 2017Funding: FWO research grant KAN
- Modulation of the tumor micro-environment in Multiple Myeloma, are exosomes involved?From1 Jan 2016 → 31 Dec 2019Funding: FWO research project (including WEAVE projects)
- Exosomal communication in Multiple Myeloma: friend or foe?From1 Oct 2015 → 30 Sep 2019Funding: FWO fellowships
- Bilateral cooperation in the framework of mutual doctoral fairy i.h.k. Joint PhD VUB University of Bari Aldo Modo, Luigia Rao.From1 Jan 2014 → 31 Dec 2014Funding: University - Project driven research
Publications
1 - 10 of 147
- Fueling CARs(2024)
Authors: Arne Van der Vreken, Karin Vanderkerken, Elke De Bruyne, Kim De Veirman, Karine Breckpot, Eline Menu
- AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia(2024)
Authors: Niels Vandewalle, Hatice Satilmis, Emma Verheye, Rong Fan, Yanmeng Wang, Timo W M De Groof, Jessica Bridoux, Tessa kerre, Nathan De Beule, Ann De Becker, et al.
Pages: 2656-2674 - S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma(2024)
Authors: Yanmeng Wang, Catharina Muylaert, Arne Wyns, Philip Vlummens, Kim De Veirman, Karin Vanderkerken, Esther Zaal, Celia R. Berkers, Jérome Moreaux, Elke De Bruyne, et al.
Pages: 256-271 - Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid Leukemia(2023)
Authors: Rong Fan, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Elke De Bruyne, Eline Menu, Nathan De Beule, Ann De Becker, G Ates, A Massie, et al.
Pages: 188-199 - RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma(2023)
Authors: Martina Emde-Rajaratnam, Susanne Beck, Vladimir Benes, Hans Jürgen Salwender, Uta Bertsch, Christoph Scheid, Mathias Hänel, Katja Weisel, Thomas Hielscher, Marc S Raab, et al.
- Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment(2023)
Authors: Hannah Egan, Oliver Treacy, Kevin Lynch, Niamh A Leonard, Grace O'Malley, Eileen Reidy, Aoise O'Neill, Shania M Corry, Kim De Veirman, Karin Vanderkerken, et al.
- Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis(2023)
Authors: Arne Van der Vreken, Inge Oudaert, G Ates, Sylvia Faict, Philip Vlummens, Hatice Satilmis, Rong Fan, Anke Maes, A Massie, Kim De Veirman, et al.
Pages: 112-123 - Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma(2023)
Authors: Rong Fan, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Philip Vlummens, Anke Maes, Catharina Muylaert, Elke De Bruyne, Eline Menu, Holly Evans, et al.
- Targeting the β2 -adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolism(2023)
Authors: Hatice Satilmis, Emma Verheye, Philip Vlummens, Inge Oudaert, Niels Vandewalle, Rong Fan, Jennifer M Knight, Nathan De Beule, G Ates, A Massie, et al.
Pages: 69–80 - Application of epigenetic-targeting agents to confer immune modulation in cancer(2023)
Authors: L De Beck, Karine Breckpot, Karin Vanderkerken, Ken Maes
Number of pages: 247